Today, blunt headlines suggest that more than 400K people are likely to miss out on early stages of cancer diagnosis in the upcoming 10 years. The shortage on the part of NHS is being mentioned to as a part of “persistence failures” from group One Cancer Voice, which comes across as a collection of over 50 cancer charities inclusive of Brain Tumor Research.
10-Year Cancer Plan
The 10-year Cancer Plan devised by Health Secretary Sajid Javid has seen the response mentioned above. This group has come up with 10 tests that say that unless and until they are met the cancer plan can’t attain success in delivery of transformative and world-leading change.
Amongst the tests, there is a need for increasing clinical research capacity with the health service staff that has access to dedicated training and research time. The group is also asking for opportunity for participating in the clinical trials. The group claims that close to 78% of the people would get diagnosed at the 1st or second stage with incorporation of the above steps.
Besides, a new-fangled study is being conducted at the University of Birmingham regarding a cannabis-oriented drug that could help the ones suffering from brain tumors. As of now, 15 NHS hospitals are witnessing conduction of phase two trial, which is being funded by The Brain Tumor Charity.
What’s with University of Birmingham?
The first 27 patients have shown promising results on this count. As per the University of Birmingham, this phase two trial will check if addition of Sativex to chemotherapy would result in extension of life for loads of people diagnosed with recurrent glioblastoma that does have survival of less than 10 months on an average.
Prof. Susan Short is leading this trial. It is expected to last for 3 years and recruits close to 230 patients. Prof. Pam Kearns, Director of the Cancer Research UK Clinical Trials Unit, states that treating glioblastomas is pretty challenging. In spite of surgery, chemotherapy, and radiotherapy, almost every brain tumor re-grows within one year, and there are limited options for the patients who suffer from these.
Cannaboids are known to have well-described outcomes in brain and there has been so much interest in their use all across various types of cancers over a period of time. Glioblastoma brain tumors are reported to be well-responsive to cannaboids on cell surfaces. Also, such glioblastoma cells have been subject to laboratory studies, which show that the growth of tumor cells could be stunted. This is how cannaboids could be useful.
Recent studies show that exclusive combination of cannaboids through oral means could be added to something called “temozolomide chemotherapy”. The studies are still ongoing, just to know if the drug could aid the glioblastoma patients in living longer.
If the trial gives out positive results, it could go in history as the major victory for medicinal cannabis, i.e. a plant having potential of helping numerous patients all across the UK with several conditions.
The healthcare personnel are looking forward to use medical cannabis to treat prostate cancer, bowel cancer, epilepsy, PTSD, ADHD, anxiety, chronic pain, Crohn’s disease, and brain tumors. Let’s wait and watch!